Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 14/20 | 0.59 |
| ▸ | FFAR4 | Q5NUL3 | 12/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TSPO | P30536 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
| ▸ | RXRG | P48443 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30637597 | 1.00 | FFAR1 (0.59) | FFAR1FFAR4POLBNPSR1TSPO | |
| Hydrochloric Acid SCHEMBL30461911 | 0.98 | FFAR1 (0.58) | FFAR1FFAR4POLBNPSR1TSPO | |
| SCHEMBL6956901 | 0.91 | FFAR1 (0.50) | FFAR1FFAR4MAOBHTR2AHTR2C | |
| SCHEMBL15808566 | 0.87 | F13A1 (0.53) | FFAR1FFAR4MAOBHTR2AHTR2C | |
| SCHEMBL3576683 | 0.86 | MAOB (0.47) | FFAR1FFAR4MAOBHTR2AHTR2C | |
| SCHEMBL29009751 | 0.86 | F13A1 (0.56) | FFAR1FFAR4MAOBHTR2AHTR2C | |
| SCHEMBL10277328 | 0.86 | F13A1 (0.56) | FFAR1FFAR4MAOBHTR2AHTR2C | |
| SCHEMBL4872028 | 0.85 | POLB (0.60) | FFAR1FFAR4POLBNPSR1 | |
| SCHEMBL1478187 | 0.85 | FFAR1 (0.51) | FFAR1FFAR4POLBNPSR1 | |
| SCHEMBL7014207 | 0.84 | MIF (0.52) | FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117143097-A | Beta-carbopol compound, preparation method thereof and application of beta-carbopol compound in resisting Alzheimer disease | 中国人民解放军北部战区总医院 | 2023-12-01 | — | — | CN | claimed |
| EP-4743175-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Aconcagua Bio, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4626876-A1 | MICROBIOCIDAL TETRAHYDROISOQUINOLINE DERIVATIVES | Syngenta Crop Protection AG (CH) | 2025-10-08 | — | — | EP | disclosed |
| US-12404265-B2 | Substituted pyridine derivatives as SARM1 inhibitors | NURA BIO, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250051355-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ACONCAGUA BIO, INC. | 2025-02-13 | — | — | US | disclosed |
| WO-2025015269-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ACONCAGUA BIO, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| WO-2024115509-A1 | MICROBIOCIDAL TETRAHYDROISOQUINOLINE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2024-06-06 | — | — | WO | disclosed |
| US-11970481-B1 | Substituted pyridine derivatives as SARM1 inhibitors | NURA BIO, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| US-20240116901-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | NURA BIO, INC. | 2024-04-11 | — | — | US | disclosed |
| CN-117143097-A | Beta-carbopol compound, preparation method thereof and application of beta-carbopol compound in resisting Alzheimer disease | 中国人民解放军北部战区总医院 | 2023-12-01 | — | — | CN | disclosed |
| CN-1044811-C | Pyrrolopyridazine derivatives | SANKYO CO (JP) | 1999-08-25 | — | — | CN | disclosed |
| US-5872118-A | RELAXATION OF SKELETAL MUSCLE IN SPASTIC, HYPERTONIC AND HYPERKINETIC CONDITIONS | GLAXO WELLCOME INC. (US) | 1999-02-16 | — | — | US | disclosed |
| EP-0742218-A1 | PYRROLOPYRIDAZINE DERIVATIVE | SANKYO COMPANY LIMITED (JP) | 1996-11-13 | — | — | EP | disclosed |
| EP-0699180-A1 | BICYCLIC AMIDE DERIVATIVES AND THEIR USE AS MUSCLE RELAXANTS | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-03-06 | — | — | EP | disclosed |
| EP-0401166-B1 | Nitrogen-containing titanocenes and their use | CIBA GEIGY AG (CH) | 1995-02-22 | — | — | EP | disclosed |
| WO-1994026693-A1 | BICYCLIC AMIDE DERIVATIVES AND THEIR USE AS MUSCLE RELAXANTS | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-11-24 | — | — | WO | disclosed |
| WO-1994026692-A1 | BICYCLIC AMIDE DERIVATIVES AND THEIR USE AS MUSCLE RELAXANTS | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-11-24 | — | — | WO | disclosed |
| EP-0553107-A1 | PROTEIN KINASE C MODULATORS WITH ANTI-INFLAMMATORY AND ANTIVIRAL ACTIVITY | PROCYON PHARMACEUTICALS, INC. (US) | 1993-08-04 | — | — | EP | disclosed |
| US-5068371-A | Photoinitiators for polymerization | CIBA-GEIGY CORPORATION (US) | 1991-11-26 | — | — | US | disclosed |
| EP-0401166-A2 | Nitrogen-containing titanocenes and their use | CIBA-GEIGY AG (CH) | 1990-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404265-B2 | Substituted pyridine derivatives as SARM1 inhibitors | SARM1, SARNP, ADRM1 | FFAR1 4246/4885FFAR4 4580/4885POLB 2207/4885 |
| US-11970481-B1 | Substituted pyridine derivatives as SARM1 inhibitors | SARM1, SARNP, ADRM1 | FFAR1 4246/4885FFAR4 4580/4885POLB 2207/4885 |
| US-20240116901-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | SARM1, SARNP, ADRM1 | FFAR1 4246/4885FFAR4 4580/4885POLB 2207/4885 |
| US-20250051355-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | IAPP, GIPR, GPR119 | FFAR1 190/4885FFAR4 271/4885POLB 4283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.